Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting…
ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for…
Generated record quarterly net revenues of $190.6 million, representing year-over-year growth of 44.8%Total Rare Disease quarterly net revenue of $87.0…
LONDON, MADRID, and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin company, announced it has recently…
Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as…
Genetic testing can be critical to ensuring the early diagnosis and proper treatment of serious disease for patients of all…
Dual AI engines in SmartSpeed Precise SmartSpeed Precise pelvis clinical image SmartSpeed Precise knee clinical image SmartSpeed Precise sinus clinical…
SARASOTA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for…
AlterDiag has signed a long-term strategic partnership agreement with the Institut Pasteur for the development of new single-domain antibodies-based rapid…
FREMONT, Calif., Feb. 24, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of…
